The FDA granted approval based on phase I/II open-label multicenter research that included patients with metastatic solid tumors [33]. Durvalumab demonstrated an ORR of 61 patients across three phase 1/2 trials [33]. Responses were more significant (46%) for groups with high PD-L1 expression (defined as 25% positive tumor or infiltrating cell) compared to none in low expression levels. Here, CD274 is linked to neoplasm.